{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:52:00Z","timestamp":1766087520399},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11912-020-0889-9","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T21:02:26Z","timestamp":1582837346000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Proton Beam Therapy in Liver Malignancies"],"prefix":"10.1007","volume":"22","author":[{"given":"Osman","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santanu","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason K.","family":"Molitoris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"889_CR1","unstructured":"Cancer of the Liver and Intrahepatic Bile Duct - Cancer Stat Facts https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html. Accessed 11 Nov 2019."},{"key":"889_CR2","unstructured":"Annual Report to the Nation 2019: National Cancer Statistics https:\/\/seer.cancer.gov\/report_to_nation\/statistics.html#new. Accessed 11 Nov 2019."},{"key":"889_CR3","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Tao R, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol. 2016;34:219\u201326. This study provides evidence for dose-escalation in the treatment of intrahepatic cholangiocarcinoma showing a statistically significant improvement of local control and overall survival with BED greater than 80.5Gy.","DOI":"10.1200\/JCO.2015.61.3778"},{"key":"889_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/02841860600904821","volume":"45","author":"J Wulf","year":"2006","unstructured":"Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45:838\u201347.","journal-title":"Acta Oncol"},{"key":"889_CR5","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","volume":"27","author":"MT Lee","year":"2009","unstructured":"Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585\u201391.","journal-title":"J Clin Oncol"},{"key":"889_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijrobp.2008.03.062","volume":"73","author":"R McCammon","year":"2009","unstructured":"McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73:112\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"889_CR7","doi-asserted-by":"crossref","unstructured":"\u2022 Velec, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017(5):939\u201346. This study establishes liver dose constraints conveying the importance of sparing threshold volumes of liver from even low doses of radiation.","DOI":"10.1016\/j.ijrobp.2017.01.221"},{"issue":"1","key":"889_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijrobp.2019.02.032","volume":"105","author":"Hsieh","year":"2019","unstructured":"Hsieh, et al. Predictors of radiation-induced liver disease in eastern and western patients with hepatocellular carcinoma undergoing proton beam therapy. Int J Radiat Oncol Biol Phys. 2019;105(1):73\u201386.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"889_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.radonc.2009.11.004","volume":"94","author":"N Kopek","year":"2010","unstructured":"Kopek N, Holt MI, Hansen AT, Hoyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol. 2010;94:47\u201352.","journal-title":"Radiother Oncol"},{"issue":"10","key":"889_CR10","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1158\/1078-0432.CCR-04-1350","volume":"11","author":"Chiba","year":"2005","unstructured":"Chiba, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11(10):3799\u2013805.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"889_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ijrobp.2008.10.073","volume":"74","author":"Fukumitsu","year":"2009","unstructured":"Fukumitsu, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74(3):831\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"889_CR12","doi-asserted-by":"crossref","unstructured":"Nakayama, et al. Proton beam therapy for hepatocellular carcinoma. Cancer. 2009:5499\u2013506.","DOI":"10.1002\/cncr.24619"},{"key":"889_CR13","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1053\/j.gastro.2004.09.033","volume":"127","author":"Bush","year":"2004","unstructured":"Bush, et al. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology. 2004;127:S138\u201393.","journal-title":"Gastroenterology"},{"key":"889_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.radonc.2018.10.041","volume":"133","author":"Chadha","year":"2019","unstructured":"Chadha, et al. Proton beam therapy outcomes of localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019;133:54\u201361.","journal-title":"Radiother Oncol"},{"issue":"5","key":"889_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.21037\/jgo.2019.08.03","volume":"10","author":"Hasan","year":"2019","unstructured":"Hasan, et al. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of a biologically effective dose escalation. J Gastrointest Oncol. 2019;10(5):999\u20131009.","journal-title":"J Gastrointest Oncol"},{"key":"889_CR16","doi-asserted-by":"crossref","unstructured":"\u2022 Sanford, et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. Int J Radiat Oncol Biol Phys. 2019;105(1):64\u201372. This retrospective study provides the foundation for pursuing large prospective studies, such as GI-003 comparing photons and protons as there is a suggestion that liver sparing with protons leads to improvements in overall survival.","DOI":"10.1016\/j.ijrobp.2019.01.076"},{"key":"889_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","volume":"34","author":"Hong","year":"2015","unstructured":"Hong, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2015;34:460\u20138.","journal-title":"J Clin Oncol"},{"key":"889_CR18","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"Bujold","year":"2013","unstructured":"Bujold, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631\u20139.","journal-title":"J Clin Oncol"},{"key":"889_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-9-26","volume":"9","author":"C Makita","year":"2014","unstructured":"Makita C, Nakamura T, Takada A, Takayama K, Suzuki M, Ishikawa Y, et al. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat Oncol. 2014;9:1\u20137. https:\/\/doi.org\/10.1186\/1748-717X-9-26.","journal-title":"Radiat Oncol"},{"key":"889_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/jgh.12843","volume":"30","author":"A Ohkawa","year":"2015","unstructured":"Ohkawa A, Mizumoto M, Ishikawa H, Abei M, Fukuda K, Hashimoto T, et al. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. J Gastroenterol Hepatol. 2015;30:957\u201363.","journal-title":"J Gastroenterol Hepatol"},{"key":"889_CR21","doi-asserted-by":"crossref","unstructured":"Ohri N, Tome WA, Mendez Romero A, et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys. 2018.","DOI":"10.1016\/j.ijrobp.2017.12.288"},{"key":"889_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.surg.2016.11.034","volume":"161","author":"LE Colbert","year":"2017","unstructured":"Colbert LE, Cloyd JM, Koay EJ, Crane CH, Vauthey JN. Proton beam radiation as salvage therapy for bilateral colorectal liver metastases not amenable to second-stage hepatectomy. Surgery. 2017;161:1543\u20138.","journal-title":"Surgery"},{"key":"889_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.radonc.2015.09.011","volume":"117","author":"N Fukumitsu","year":"2015","unstructured":"Fukumitsu N, Okumura T, Takizawa D, Makishima H, Numajiri H, Murofushi K, et al. Proton beam therapy for metastatic liver tumors. Radiother Oncol. 2015;117:322\u20137.","journal-title":"Radiother Oncol"},{"key":"889_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jrr\/rrw102","volume":"58","author":"N Fukumitsu","year":"2017","unstructured":"Fukumitsu N, Okumura T, Takizawa D, Numajiri H, Ohnishi K, Mizumoto M, et al. Proton beam therapy for liver metastases from gastric cancer. J Radiat Res. 2017;58:357\u201362.","journal-title":"J Radiat Res"},{"issue":"1","key":"889_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3892\/mco.2017.1283","volume":"7","author":"N Fukumitsu","year":"2017","unstructured":"Fukumitsu N, Okumura T, Numajiri H, Takizawa D, Ohnishi K, Mizumoto M, et al. Follow-up study of liver metastasis from breast cancer treated by proton beam therapy. Mol Clin Oncol. 2017;7(1):56\u201360. https:\/\/doi.org\/10.3892\/mco.2017.1283.","journal-title":"Mol Clin Oncol"},{"key":"889_CR26","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Hong T, Wo J, Borger D, Yeap B, McDonnell E, et al. Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. JNCI: Journal of the National Cancer Institute. 2017;109(9):djx031. https:\/\/doi.org\/10.1093\/jnci\/djx031. This is the largest prospective proton SBRT for liver metastases showing that the technique is safe and effective, even in large tumors.","DOI":"10.1093\/jnci\/djx031"},{"issue":"1","key":"889_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.21037\/jgo.2018.08.17","volume":"10","author":"JI Kang","year":"2019","unstructured":"Kang JI, Sufficool DC, Hsueh CT, et al. A phase I trial of proton stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol. 2019;10(1):112\u20137. https:\/\/doi.org\/10.21037\/jgo.2018.08.17.","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"889_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.radonc.2017.03.004","volume":"123","author":"Y Oshiro","year":"2017","unstructured":"Oshiro Y, Mizumoto M, Okumura T, Fukuda K, Fukumitsu N, Abei M. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. Radiother Oncol. 2017;123(2):240\u20135.","journal-title":"Radiother Oncol"},{"key":"889_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.prro.2018.04.012","volume":"8","author":"SGR McDuff","year":"2018","unstructured":"McDuff SGR, Remillard KA, Zheng H. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018;8:414\u201321.","journal-title":"Pract Radiat Oncol"},{"key":"889_CR30","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1088\/0031-9155\/57\/11\/R99","volume":"57","author":"H Paganetti","year":"2012","unstructured":"Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol. 2012;57:R99\u2013117.","journal-title":"Phys Med Biol"},{"key":"889_CR31","doi-asserted-by":"publisher","first-page":"20120288","DOI":"10.1259\/bjr.20120288","volume":"86","author":"SE McGowan","year":"2013","unstructured":"McGowan SE, Burnet NG, Lomax AJ. Treatment planning optimisation in proton therapy. Br J Radiol. 2013;86:20120288.","journal-title":"Br J Radiol"},{"key":"889_CR32","doi-asserted-by":"publisher","first-page":"235006","DOI":"10.1088\/1361-6560\/aaecfc","volume":"63","author":"T Pfeiler","year":"2018","unstructured":"Pfeiler T, Ahmad Khalil D, Ayadi M, et al. Motion effects in proton treatments of hepatocellular carcinoma-4d robustly optimised pencil beam scanning plans versus double scattering plans. Phys Med Biol. 2018;63:235006.","journal-title":"Phys Med Biol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0889-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-020-0889-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0889-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T01:21:26Z","timestamp":1614302486000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-020-0889-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-0889-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"27 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}],"article-number":"30"}}